Home » NEORX ANNOUNCES ORPHAN-DRUG DESIGNATION FOR PICOPLATIN
NEORX ANNOUNCES ORPHAN-DRUG DESIGNATION FOR PICOPLATIN
NeoRx has received orphan drug designation from the FDA for the company's investigational
product picoplatin, a next-generation platinum therapy, for the treatment of
small cell lung cancer (SCLC).
Picoplatin is an intravenous platinum chemotherapeutic agent specifically designed
to overcome platinum resistance. It is currently being studied in an ongoing
randomized, open-label, multicenter Phase II clinical trial in patients with
platinum-resistant or refractory SCLC. The trial is presently open to enrollment
at approximately 25 clinical sites throughout the U.S. and Canada. NeoRx plans
to commence clinical trials of picoplatin in Europe in the first quarter of
2006.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May